CurrentAvMedPolicy N/A

Dysport (abotulinumtoxinA) prior authorization for botulinum toxin type A injections

Defines clinical prior authorization criteria for coverage of Dysport (abotulinumtoxinA) injections for various indications (spasticity, dystonia, anal fissures, drooling); documents dosing, treatment intervals, and required supporting documentation for prior authorization requests. Cosmetic indications are excluded.

Policy Summary

PayerAvMed

PolicyDysport (abotulinumtoxinA) prior authorization for botulinum toxin type A injections

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit a completed prior authorization form with the prescriber's printed name and signature and include all supporting documentation (labs, diagnostics, chart notes) to avoid delays or denial.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

>=12Minimum retreatment interval for most indications

1000Common maximum single-session dose referenced

500-1500Typical adult session dosing ranges

Not acceptableUse of samples

Policy Snapshot

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

This document defines prior authorization criteria for Dysport (abotulinumtoxinA) injections across multiple neurologic and muscular indications, including pediatric and adult spasticity, upper limb spasticity, cervical dystonia, cerebral palsy–related spasticity, anal fissures, and drooling (chronic sialorrhea). Cosmetic indications are explicitly excluded from coverage. The criteria specify required prescriber documentation, diagnosis confirmation, dosing ranges, and treatment intervals that must be met for authorization.

ScopeDefines clinical prior authorization criteria for coverage of Dysport (abotulinumtoxinA) injections for various indications (spasticity, dystonia, anal fissures, drooling) and documents dosing, treatment intervals, and documentation requirements.

StatusCURRENT

Minimum retreatment interval for most indications>= 12 weeks

Common maximum single-session dose1000 units (kg‑based limits may apply)

Typical adult session dosing ranges500-1500 units depending on indication and muscles treated

Samples ruleUse of samples to initiate therapy does not meet step edit/preauthorization criteria and will not substitute for required prior therapy documentation.

Medical Necessity Criteria by Indication

General Authorization Requirement

All criteria must be met for approval. Cosmetic indications are excluded.

ALL of the following

Completed and signed prior authorization form with prescriber signature and required member/prescriber information (phone, fax, NPI).
If incomplete, authorization may be delayed or denied.
Documentation to support each checked clinical criterion must be provided (lab results, diagnostics, chart notes).
Use of samples to initiate therapy does not meet step edit/preauthorization criteria.

ALL of the following

Prescriber must sign and clearly print name on the request; preprinted stamps are not valid.
All other required member and prescriber contact information must be provided (phone, fax, NPI, date of birth, weight if applicable).

ALL of the following

Incomplete, incorrect, or illegible information may delay the authorization process.

Pediatric Lower Limb Spasticity (> 2 years)